Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells

Biomaterials

Volumn 35, Issue 1, 2014, Pages 269-277

  Sunshine, Joel C ^a   Perica, Karlo ^a   Schneck, Jonathan P ^a   Green, Jordan J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Artificial antigen presenting cells; Biomimetic; Ellipsoidal; Immunotherapy; Microparticles; Particle shape

Indexed keywords

ARTIFICIAL ANTIGEN; ELLIPSOIDAL; IMMUNOTHERAPY; MICRO-PARTICLES; PARTICLE SHAPE;

ANTIGENS; ASPECT RATIO; BIOMIMETICS; CELLS; DERMATOLOGY; ONCOLOGY; SPHERES; T-CELLS;

CYTOLOGY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONJUGATION; IN VITRO STUDY; LEUKOCYTE MICROPARTICLE; MELANOMA; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SYNTHESIS; T LYMPHOCYTE ACTIVATION;

ARTIFICIAL ANTIGEN PRESENTING CELLS; BIOMIMETIC; ELLIPSOIDAL; IMMUNOTHERAPY; MICROPARTICLES; PARTICLE SHAPE;

ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL SHAPE; HUMANS; LYMPHOCYTE ACTIVATION; MICROSCOPY, ELECTRON, SCANNING;

EID: 84887026240     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.050     Document Type: Article

References (41)

1. Fletcher D.A., Mullins R.D. Cell mechanics and the cytoskeleton. Nature 2010, 463(7280):485-492.
2. Dustin M.L. T-cell activation through immunological synapses and kinapses. Immunol Rev 2008, 221(221):77-89.
3. Dykstra M., Cherukuri A., Sohn H.W., Tzeng S.J., Pierce S.K. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 2003, 21:457-481.
4. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285(5425):221-227.
5. Lee K.H., Holdorf A.D., Dustin M.L., Chan A.C., Allen P.M., Shaw A.S. Tcell receptor signaling precedes immunological synapse formation. Science 2002, 295(5559):1539-1542.
6. Monks C.R., Freiberg B.A., Kupfer H., Sciaky N., Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998, 395(6697):82-86.
7. Doh J., Irvine D.J. Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse structure formation in T cells. Proc Natl Acad Sci U S A 2006, 103(15):5700-5705.
8. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., Schneck J.P. Exvivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003, 9(5):619-625.
9. Ugel S., Zoso A., De Santo C., Li Y., Marigo I., Zanovello P., et al. Invivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res 2009, 69(24):9376-9384.
10. Mescher M.F. Surface contact requirements for activation of cytotoxic T lymphocytes. JImmunol 1992, 149(7):2402-2405.
11. Han H., Peng J.R., Chen P.C., Gong L., Qiao S.S., Wang W.Z., et al. Anovel system of artificial antigen-presenting cells efficiently stimulates flu peptide-specific cytotoxic T cells invitro. Biochem Biophys Res Commun 2011, 411(3):530-535.
12. Steenblock E.R., Fadel T., Labowsky M., Pober J.S., Fahmy T.M. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. JBiol Chem 2011, 286(40):34883-34892.
13. Steenblock E.R., Fahmy T.M. Acomprehensive platform for exvivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 2008, 16(4):765-772.
14. Ndhlovu Z.M., Oelke M., Schneck J.P., Griffin D.E. Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A 2010, 107(8):3669-3674.
15. Ito F., Carr A., Svensson H., Yu J., Chang A.E., Li Q. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. JImmunother 2003, 26(3):222-233.
16. Lum L.G., LeFever A.V., Treisman J.S., Garlie N.K., Hanson J.P. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. JImmunother 2001, 24(5):408-419.
17. Taylor P.A., Lees C.J., Blazar B.R. The infusion of exvivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99(10):3493-3499.
18. Sunshine J.C., Green J.J. Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine 2013, 8(7):1173-1189.
19. Balmert S.C., Little S.R. Biomimetic delivery with micro- and nanoparticles. Adv Mater 2012, 24(28):3757-3778.
20. Wang J., Byrne J.D., Napier M.E., DeSimone J.M. More effective nanomedicines through particle design. Small 2011, 7(14):1919-1931.
21. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A 2006, 103(13):4930-4934.
22. Sharma G., Valenta D.T., Altman Y., Harvey S., Xie H., Mitragotri S., et al. Polymer particle shape independently influences binding and internalization by macrophages. JControl Release 2010, 147(3):408-412.
23. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. JControl Release 2007, 121(1-2):3-9.
24. Devarajan P.V., Jindal A.B., Patil R.R., Mulla F., Gaikwad R.V., Samad A. Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. JPharm Sci 2010, 99(6):2576-2581.
25. Harris B.J., Dalhaimer P. Particle shape effects invitro and invivo. Front Biosci (Schol Ed) 2012, 4:1344-1353.
26. Barua S., Yoo J.W., Kolhar P., Wakankar A., Gokarn Y.R., Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A 2013, 110(9):3270-3275.
27. Curtsinger J., Deeths M.J., Pease P., Mescher M.F. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. JImmunol Methods 1997, 209(1):47-57.
28. Maus M.V., Thomas A.K., Leonard D.G., Allman D., Addya K., Schlienger K., et al. Exvivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002, 20(2):143-148.
29. Steenblock E.R., Wrzesinski S.H., Flavell R.A., Fahmy T.M. Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. Expert Opin Biol Ther 2009, 9(4):451-464.
30. Suhoski M.M., Golovina T.N., Aqui N.A., Tai V.C., Varela-Rohena A., Milone M.C., et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007, 15(5):981-988.
31. Yoo J.W., Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci U S A 2010, 107(25):11205-11210.
32. Schneck J.P., Slansky J.E., O'Herrin S.M., Greten T.F. Monitoring antigen-specific T cells using MHC-Ig dimers. Current protocols in immunology 2001, J.E. Coligan (Ed.).
33. Durai M., Krueger C., Ye Z., Cheng L., Mackensen A., Oelke M., et al. Invivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 2009, 58(2):209-220.
34. Rothstein S.N., Federspiel W.J., Little S.R. Aunified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices. Biomaterials 2009, 30(8):1657-1664.
35. Batycky R.P., Hanes J., Langer R., Edwards D.A. Atheoretical model of erosion and macromolecular drug release from biodegrading microspheres. JPharm Sci 1997, 86(12):1464-1477.
36. von Burkersroda F., Schedl L., Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002, 23(21):4221-4231.
37. Gottschalk R.A., Hathorn M.M., Beuneu H., Corse E., Dustin M.L., Altan-Bonnet G., et al. Distinct influences of peptide-MHC quality and quantity on invivo T-cell responses. Proc Natl Acad Sci U S A 2012, 109(3):881-886.
38. Arens R., Schoenberger S.P. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev 2010, 235(1):190-205.
39. Bullock T.N., Mullins D.W., Engelhard V.H. Antigen density presented by dendritic cells invivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. JImmunol 2003, 170(4):1822-1829.
40. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(4):247-258.
41. Kroger C.J., Alexander-Miller M.A. Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. JImmunol 2007, 179(2):748-751.